{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:10:18Z","timestamp":1791897018862,"version":"4.3.4"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T00:00:00Z","timestamp":1364947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s40263-013-0055-0","type":"journal-article","created":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T11:22:22Z","timestamp":1364901742000},"page":"345-352","source":"Crossref","is-referenced-by-count":43,"title":["Targeting Sirtuin-1 in Huntington\u2019s Disease: Rationale and Current Status"],"prefix":"10.1007","volume":"27","author":[{"given":"Wenzhen","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,3]]},"reference":[{"key":"55_CR1","doi-asserted-by":"crossref","unstructured":"The Huntington\u2019s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell. 1993;72(6):971\u201383.","DOI":"10.1016\/0092-8674(93)90585-E"},{"issue":"4","key":"55_CR2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clin Genet. 2004;65(4):267\u201377.","journal-title":"Clin Genet"},{"issue":"9751","key":"55_CR3","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(10)61989-7","volume":"376","author":"T Hoppitt","year":"2010","unstructured":"Hoppitt T, Calvert M, Pall H, Rickards H, Sackley C. Huntington\u2019s disease. Lancet. 2010;376(9751):1463\u20134.","journal-title":"Lancet"},{"issue":"1","key":"55_CR4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83\u201398.","journal-title":"Lancet Neurol"},{"issue":"10","key":"55_CR5","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","volume":"101","author":"NS Wexler","year":"2004","unstructured":"Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset. Proc Natl Acad Sci USA. 2004;101(10):3498\u2013503.","journal-title":"Proc Natl Acad Sci USA"},{"key":"55_CR6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1196\/annals.1427.018","volume":"1147","author":"SE Browne","year":"2008","unstructured":"Browne SE. Mitochondria and Huntington\u2019s disease pathogenesis: insight from genetic and chemical models. Ann N Y Acad Sci. 2008;1147:358\u201382.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"55_CR7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410390317","volume":"39","author":"M Gu","year":"1996","unstructured":"Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington\u2019s disease caudate nucleus. Ann Neurol. 1996;39(3):385\u20139.","journal-title":"Ann Neurol"},{"issue":"8717","key":"55_CR8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/0140-6736(90)92242-A","volume":"336","author":"VM Mann","year":"1990","unstructured":"Mann VM, Cooper JM, Javoy-Agid F, Agid Y, Jenner P, Schapira AH. Mitochondrial function and parental sex effect in Huntington\u2019s disease. Lancet. 1990;336(8717):749.","journal-title":"Lancet"},{"issue":"5","key":"55_CR9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/hmg\/dds503","volume":"22","author":"E Napoli","year":"2013","unstructured":"Napoli E, Wong S, Hung C, Ross-Inta C, Bomdica P, Giulivi C. Defective mitochondrial disulfide relay system, altered mitochondrial morphology and function in Huntington\u2019s disease. Hum Mol Genet. 2013;22(5):989\u20131004.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"55_CR10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1042\/BJ20071619","volume":"412","author":"S Imarisio","year":"2008","unstructured":"Imarisio S, Carmichael J, Korolchuk V, Chen CW, Saiki S, Rose C, et al. Huntington\u2019s disease: from pathology and genetics to potential therapies. Biochem J. 2008;412(2):191\u2013209.","journal-title":"Biochem J."},{"issue":"5","key":"55_CR11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cmet.2006.10.004","volume":"4","author":"P Weydt","year":"2006","unstructured":"Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, et al. Thermoregulatory and metabolic defects in Huntington\u2019s disease transgenic mice implicate PGC-1alpha in Huntington\u2019s disease neurodegeneration. Cell Metab. 2006;4(5):349\u201362.","journal-title":"Cell Metab"},{"issue":"1","key":"55_CR12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","volume":"127","author":"L Cui","year":"2006","unstructured":"Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006;127(1):59\u201369.","journal-title":"Cell"},{"issue":"3","key":"55_CR13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10863-010-9290-y","volume":"42","author":"C Turner","year":"2010","unstructured":"Turner C, Schapira AH. Mitochondrial matters of the brain: the role in Huntington\u2019s disease. J Bioenerg Biomembr. 2010;42(3):193\u20138.","journal-title":"J Bioenerg Biomembr"},{"issue":"3","key":"55_CR14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10863-010-9287-6","volume":"42","author":"JM Oliveira","year":"2010","unstructured":"Oliveira JM. Mitochondrial bioenergetics and dynamics in Huntington\u2019s disease: tripartite synapses and selective striatal degeneration. J Bioenerg Biomembr. 2010;42(3):227\u201334.","journal-title":"J Bioenerg Biomembr"},{"issue":"4\u20135","key":"55_CR15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.brainresbull.2009.07.010","volume":"80","author":"RA Quintanilla","year":"2009","unstructured":"Quintanilla RA, Johnson GV. Role of mitochondrial dysfunction in the pathogenesis of Huntington\u2019s disease. Brain Res Bull. 2009;80(4\u20135):242\u20137.","journal-title":"Brain Res Bull"},{"key":"55_CR16","doi-asserted-by":"crossref","unstructured":"Beal MF. Mitochondria and neurodegeneration. Novartis Found Symp. 2007;287:183\u201392 (discussion 92\u20136).","DOI":"10.1002\/9780470725207.ch13"},{"issue":"2","key":"55_CR17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1172\/JCI45691","volume":"121","author":"F Mochel","year":"2011","unstructured":"Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest. 2011;121(2):493\u20139.","journal-title":"J Clin Invest"},{"key":"55_CR18","volume-title":"Rego AC","author":"TR Rosenstock","year":"2010","unstructured":"Rosenstock TR, Duarte AI. Rego AC. Curr Drug Targets: Mitochondrial-associated metabolic changes and neurodegeneration in Huntington\u2019s disease\u2014from clinical features to the bench; 2010."},{"issue":"11\u201312","key":"55_CR19","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1089\/ars.2006.8.2061","volume":"8","author":"SE Browne","year":"2006","unstructured":"Browne SE, Beal MF. Oxidative damage in Huntington\u2019s disease pathogenesis. Antioxid Redox Signal. 2006;8(11\u201312):2061\u201373.","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"55_CR20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1539\/joh.49.389","volume":"49","author":"HI Chen","year":"2007","unstructured":"Chen HI, Liou SH, Ho SF, Wu KY, Sun CW, Chen MF, et al. Oxidative DNA damage estimated by plasma 8-hydroxydeoxyguanosine (8-OHdG): influence of 4,4\u2032-methylenebis (2-chloroaniline) exposure and smoking. J Occup Health. 2007;49(5):389\u201398.","journal-title":"J Occup Health"},{"issue":"5","key":"55_CR21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.freeradbiomed.2008.05.014","volume":"45","author":"MA Sorolla","year":"2008","unstructured":"Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, Cabiscol E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med. 2008;45(5):667\u201378.","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"55_CR22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1023\/A:1010911417383","volume":"26","author":"A Santamaria","year":"2001","unstructured":"Santamaria A, Perez-Severiano F, Rodriguez-Martinez E, Maldonado PD, Pedraza-Chaverri J, Rios C, et al. Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington\u2019s disease. Neurochem Res. 2001;26(4):419\u201324.","journal-title":"Neurochem Res"},{"issue":"5746","key":"55_CR23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1126\/science.1117728","volume":"310","author":"E Nisoli","year":"2005","unstructured":"Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 2005;310(5746):314\u20137.","journal-title":"Science"},{"issue":"21","key":"55_CR24","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1101\/gad.1467506","volume":"20","author":"MC Haigis","year":"2006","unstructured":"Haigis MC, Guarente LP. Mammalian sirtuins\u2013emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006;20(21):2913\u201321.","journal-title":"Genes Dev"},{"issue":"5","key":"55_CR25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrendo.2011.225","volume":"8","author":"A Chalkiadaki","year":"2012","unstructured":"Chalkiadaki A, Guarente L. Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol. 2012;8(5):287\u201396.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"55_CR26","first-page":"89","volume":"1","author":"I Shimokawa","year":"2010","unstructured":"Shimokawa I, Trindade LS. Dietary restriction and aging in rodents: a current view on its molecular mechanisms. Aging Dis. 2010;1(2):89\u2013107.","journal-title":"Aging Dis"},{"issue":"7","key":"55_CR27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.tem.2009.03.008","volume":"20","author":"C Canto","year":"2009","unstructured":"Canto C, Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab. 2009;20(7):325\u201331.","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"55_CR28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11357-009-9104-5","volume":"31","author":"LA Wakeling","year":"2009","unstructured":"Wakeling LA, Ions LJ, Ford D. Could Sirt1-mediated epigenetic effects contribute to the longevity response to dietary restriction and be mimicked by other dietary interventions? Age (Dordr). 2009;31(4):327\u201341.","journal-title":"Age (Dordr)"},{"issue":"5","key":"55_CR29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molmed.2008.03.002","volume":"14","author":"K Maiese","year":"2008","unstructured":"Maiese K, Chong ZZ, Shang YC. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med. 2008;14(5):219\u201327.","journal-title":"Trends Mol Med"},{"issue":"1","key":"55_CR30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbrc.2008.04.176","volume":"372","author":"K Hasegawa","year":"2008","unstructured":"Hasegawa K, Wakino S, Yoshioka K, Tatematsu S, Hara Y, Minakuchi H, et al. Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun. 2008;372(1):51\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"55_CR31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/156720208785425666","volume":"5","author":"ZZ Chong","year":"2008","unstructured":"Chong ZZ, Maiese K. Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neurons through nicotinamidase and sirtuin mediated pathways. Curr Neurovasc Res. 2008;5(3):159\u201370.","journal-title":"Curr Neurovasc Res"},{"issue":"11","key":"55_CR32","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1074\/jbc.M109.090266","volume":"285","author":"M Tanno","year":"2010","unstructured":"Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S, et al. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem. 2010;285(11):8375\u201382.","journal-title":"J Biol Chem"},{"key":"55_CR33","doi-asserted-by":"crossref","unstructured":"Tsunemi T, Ashe TD, Morrison BE, Soriano KR, Au J, Roque RA, et al. PGC-1alpha rescues Huntington\u2019s disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med. 2012;4(142):142ra97.","DOI":"10.1126\/scitranslmed.3003799"},{"issue":"12","key":"55_CR34","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.4161\/auto.21862","volume":"8","author":"AR Spada La","year":"2012","unstructured":"La Spada AR. PPARGC1A\/PGC-1alpha, TFEB and enhanced proteostasis in Huntington disease: defining regulatory linkages between energy production and protein-organelle quality control. Autophagy. 2012;8(12):1845\u20137.","journal-title":"Autophagy"},{"issue":"40","key":"55_CR35","doi-asserted-by":"crossref","first-page":"9989","DOI":"10.1523\/JNEUROSCI.3257-08.2008","volume":"28","author":"G Ramadori","year":"2008","unstructured":"Ramadori G, Lee CE, Bookout AL, Lee S, Williams KW, Anderson J, et al. Brain SIRT1: anatomical distribution and regulation by energy availability. J Neurosci. 2008;28(40):9989\u201396.","journal-title":"J Neurosci"},{"issue":"1","key":"55_CR36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/genetics\/116.1.9","volume":"116","author":"J Rine","year":"1987","unstructured":"Rine J, Herskowitz I. Four genes responsible for a position effect on expression from HML and HMR in Saccharomyces cerevisiae. Genetics. 1987;116(1):9\u201322.","journal-title":"Genetics"},{"key":"55_CR37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1101\/sqb.2011.76.010629","volume":"76","author":"L Guarente","year":"2011","unstructured":"Guarente L. Sirtuins, aging, and metabolism. Cold Spring Harb Symp Quant Biol. 2011;76:81\u201390.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"23","key":"55_CR38","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMra1100831","volume":"364","author":"L Guarente","year":"2011","unstructured":"Guarente L, Franklin H. Epstein lecture: sirtuins, aging, and medicine. N Engl J Med. 2011;364(23):2235\u201344.","journal-title":"N Engl J Med"},{"issue":"Pt 6","key":"55_CR39","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1242\/jcs.081067","volume":"124","author":"T Nakagawa","year":"2011","unstructured":"Nakagawa T, Guarente L. Sirtuins at a glance. J Cell Sci. 2011;124(Pt 6):833\u20138.","journal-title":"J Cell Sci"},{"issue":"9","key":"55_CR40","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1074\/jbc.M609554200","volume":"282","author":"M Tanno","year":"2007","unstructured":"Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem. 2007;282(9):6823\u201332.","journal-title":"J Biol Chem"},{"key":"55_CR41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.pathol.4.110807.092250","volume":"5","author":"MC Haigis","year":"2010","unstructured":"Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol. 2010;5:253\u201395.","journal-title":"Annu Rev Pathol"},{"issue":"5686","key":"55_CR42","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1098014","volume":"305","author":"T Araki","year":"2004","unstructured":"Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science. 2004;305(5686):1010\u20133.","journal-title":"Science"},{"issue":"31","key":"55_CR43","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.2174\/138161211798072526","volume":"17","author":"S Srivastava","year":"2011","unstructured":"Srivastava S, Haigis MC. Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer\u2019s and Parkinson\u2019s diseases. Curr Pharm Des. 2011;17(31):3418\u201333.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"55_CR44","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2010.06.020","volume":"142","author":"G Donmez","year":"2010","unstructured":"Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell. 2010;142(2):320\u201332.","journal-title":"Cell"},{"issue":"3","key":"55_CR45","first-page":"214","volume":"1","author":"L Polito","year":"2010","unstructured":"Polito L, Kehoe PG, Forloni G, Albani D. The molecular genetics of sirtuins: association with human longevity and age-related diseases. Int J Mol Epidemiol Genet. 2010;1(3):214\u201325.","journal-title":"Int J Mol Epidemiol Genet"},{"issue":"8","key":"55_CR46","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.bbapap.2009.11.015","volume":"1804","author":"J Wang","year":"2010","unstructured":"Wang J, Fivecoat H, Ho L, Pan Y, Ling E, Pasinetti GM. The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer\u2019s disease neuropathology. Biochim Biophys Acta. 2010;1804(8):1690\u20134.","journal-title":"Biochim Biophys Acta"},{"issue":"13","key":"55_CR47","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1038\/sj.emboj.7601758","volume":"26","author":"D Kim","year":"2007","unstructured":"Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer\u2019s disease and amyotrophic lateral sclerosis. EMBO J. 2007;26(13):3169\u201379.","journal-title":"EMBO J"},{"issue":"1","key":"55_CR48","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1523\/JNEUROSCI.3442-11.2012","volume":"32","author":"G Donmez","year":"2012","unstructured":"Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against alpha-synuclein aggregation by activating molecular chaperones. J Neurosci. 2012;32(1):124\u201332.","journal-title":"J Neurosci"},{"issue":"1","key":"55_CR49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nm.2558","volume":"18","author":"M Jiang","year":"2012","unstructured":"Jiang M, Wang J, Fu J, Du L, Jeong H, West T, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington\u2019s disease through activation of multiple Sirt1 targets. Nat Med. 2012;18(1):153\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"55_CR50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.2559","volume":"18","author":"H Jeong","year":"2012","unstructured":"Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med. 2012;18(1):159\u201365.","journal-title":"Nat Med"},{"issue":"4","key":"55_CR51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/ng1534","volume":"37","author":"JA Parker","year":"2005","unstructured":"Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet. 2005;37(4):349\u201350.","journal-title":"Nat Genet"},{"issue":"23","key":"55_CR52","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1093\/hmg\/ddn273","volume":"17","author":"J Pallos","year":"2008","unstructured":"Pallos J, Bodai L, Lukacsovich T, Purcell JM, Steffan JS, Thompson LM, et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington\u2019s disease. Hum Mol Genet. 2008;17(23):3767\u201375.","journal-title":"Hum Mol Genet"},{"issue":"7365","key":"55_CR53","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature10296","volume":"477","author":"C Burnett","year":"2011","unstructured":"Burnett C, Valentini S, Cabreiro F, Goss M, Somogyvari M, Piper MD, et al. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature. 2011;477(7365):482\u20135.","journal-title":"Nature"},{"issue":"1","key":"55_CR54","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nm.2558","volume":"18","author":"M Jiang","year":"2012","unstructured":"Jiang M, Wang J, Fu J, Du L, Jeong H, West T, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington\u2019s disease through activation of multiple Sirt1 targets. Nat Med. 2012;18(1):153\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"55_CR55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.2559","volume":"18","author":"H Jeong","year":"2011","unstructured":"Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med. 2011;18(1):159\u201365.","journal-title":"Nat Med"},{"issue":"2","key":"55_CR56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.phrs.2005.01.001","volume":"52","author":"C Zuccato","year":"2005","unstructured":"Zuccato C, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M, et al. Progressive loss of BDNF in a mouse model of Huntington\u2019s disease and rescue by BDNF delivery. Pharmacol Res. 2005;52(2):133\u20139.","journal-title":"Pharmacol Res"},{"issue":"5529","key":"55_CR57","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","volume":"293","author":"C Zuccato","year":"2001","unstructured":"Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease. Science. 2001;293(5529):493\u20138.","journal-title":"Science"},{"issue":"5\u20136","key":"55_CR58","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","volume":"81","author":"C Zuccato","year":"2007","unstructured":"Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington\u2019s disease. Prog Neurobiol. 2007;81(5\u20136):294\u2013330.","journal-title":"Prog Neurobiol"},{"issue":"44","key":"55_CR59","doi-asserted-by":"crossref","first-page":"14708","DOI":"10.1523\/JNEUROSCI.1637-10.2010","volume":"30","author":"Y Xie","year":"2010","unstructured":"Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington\u2019s disease phenotypes in YAC128 mice. J Neurosci. 2010;30(44):14708\u201318.","journal-title":"J Neurosci"},{"issue":"1","key":"55_CR60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1326-6-71","volume":"6","author":"A Giralt","year":"2011","unstructured":"Giralt A, Carreton O, Lao-Peregrin C, Martin ED, Alberch J. Conditional BDNF release under pathological conditions improves Huntington\u2019s disease pathology by delaying neuronal dysfunction. Mol Neurodegener. 2011;6(1):71.","journal-title":"Mol Neurodegener"},{"issue":"5","key":"55_CR61","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1073\/pnas.0536856100","volume":"100","author":"W Duan","year":"2003","unstructured":"Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA. 2003;100(5):2911\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"55_CR62","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nbd.2008.01.015","volume":"30","author":"W Duan","year":"2008","unstructured":"Duan W, Peng Q, Masuda N, Ford E, Tryggestad E, Ladenheim B, et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington\u2019s disease. Neurobiol Dis. 2008;30(3):312\u201322.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"55_CR63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","volume":"210","author":"Q Peng","year":"2008","unstructured":"Peng Q, Masuda N, Jiang M, Li Q, Zhao M, Ross CA, et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington\u2019s disease mouse model. Exp Neurol. 2008;210(1):154\u201363.","journal-title":"Exp Neurol"},{"issue":"6","key":"55_CR64","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1210\/en.2002-0113","volume":"144","author":"W Duan","year":"2003","unstructured":"Duan W, Guo Z, Jiang H, Ware M, Mattson MP. Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology. 2003;144(6):2446\u201353.","journal-title":"Endocrinology"},{"issue":"10","key":"55_CR65","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrn2474","volume":"9","author":"E Cohen","year":"2008","unstructured":"Cohen E, Dillin A. The insulin paradox: aging, proteotoxicity and neurodegeneration. Nat Rev Neurosci. 2008;9(10):759\u201367.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"55_CR66","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cmet.2008.02.010","volume":"7","author":"B Wang","year":"2008","unstructured":"Wang B, Goode J, Best J, Meltzer J, Schilman PE, Chen J, et al. The insulin-regulated CREB coactivator TORC promotes stress resistance in Drosophila. Cell Metab. 2008;7(5):434\u201344.","journal-title":"Cell Metab"},{"issue":"18","key":"55_CR67","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1101\/gad.909001","volume":"15","author":"N Silverman","year":"2001","unstructured":"Silverman N, Maniatis T. NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev. 2001;15(18):2321\u201342.","journal-title":"Genes Dev"},{"issue":"1","key":"55_CR68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.expneurol.2010.05.006","volume":"225","author":"DJ Ho","year":"2010","unstructured":"Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF. Resveratrol protects against peripheral deficits in a mouse model of Huntington\u2019s disease. Exp Neurol. 2010;225(1):74\u201384.","journal-title":"Exp Neurol"},{"issue":"7117","key":"55_CR69","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature05354","volume":"444","author":"JA Baur","year":"2006","unstructured":"Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337\u201342.","journal-title":"Nature"},{"issue":"6","key":"55_CR70","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd2060","volume":"5","author":"JA Baur","year":"2006","unstructured":"Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493\u2013506.","journal-title":"Nat Rev Drug Discov"},{"issue":"5\u20136","key":"55_CR71","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00008877-200609000-00014","volume":"17","author":"P Kumar","year":"2006","unstructured":"Kumar P, Padi SS, Naidu PS, Kumar A. Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behav Pharmacol. 2006;17(5\u20136):485\u201392.","journal-title":"Behav Pharmacol"},{"issue":"2","key":"55_CR72","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/hmg\/ddq460","volume":"20","author":"P Maher","year":"2011","unstructured":"Maher P, Dargusch R, Bodai L, Gerard PE, Purcell JM, Marsh JL. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington\u2019s disease. Hum Mol Genet. 2011;20(2):261\u201370.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"55_CR73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mnfr.201100400","volume":"56","author":"E Scott","year":"2012","unstructured":"Scott E, Steward WP, Gescher AJ, Brown K. Resveratrol in human cancer chemoprevention\u2013choosing the \u2018right\u2019 dose. Mol Nutr Food Res. 2012;56(1):7\u201313.","journal-title":"Mol Nutr Food Res"},{"issue":"1","key":"55_CR74","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.maturitas.2012.02.004","volume":"72","author":"B Stocco","year":"2012","unstructured":"Stocco B, Toledo K, Salvador M, Paulo M, Koyama N, Torqueti Toloi MR. Dose-dependent effect of resveratrol on bladder cancer cells: chemoprevention and oxidative stress. Maturitas. 2012;72(1):72\u20138.","journal-title":"Maturitas"},{"issue":"5","key":"55_CR75","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cmet.2012.04.003","volume":"15","author":"NL Price","year":"2012","unstructured":"Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15(5):675\u201390.","journal-title":"Cell Metab"},{"issue":"1","key":"55_CR76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FBP.0b013e32834eafa3","volume":"23","author":"C Girbovan","year":"2012","unstructured":"Girbovan C, Morin L, Plamondon H. Repeated resveratrol administration confers lasting protection against neuronal damage but induces dose-related alterations of behavioral impairments after global ischemia. Behav Pharmacol. 2012;23(1):1\u201313.","journal-title":"Behav Pharmacol"},{"issue":"7170","key":"55_CR77","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nature06261","volume":"450","author":"JC Milne","year":"2007","unstructured":"Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450(7170):712\u20136.","journal-title":"Nature"},{"issue":"11","key":"55_CR78","doi-asserted-by":"crossref","first-page":"8340","DOI":"10.1074\/jbc.M109.088682","volume":"285","author":"M Pacholec","year":"2010","unstructured":"Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010;285(11):8340\u201351.","journal-title":"J Biol Chem"},{"issue":"1","key":"55_CR79","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nbd.2010.08.017","volume":"41","author":"T Hathorn","year":"2011","unstructured":"Hathorn T, Snyder-Keller A, Messer A. Nicotinamide improves motor deficits and upregulates PGC-1alpha and BDNF gene expression in a mouse model of Huntington\u2019s disease. Neurobiol Dis. 2011;41(1):43\u201350.","journal-title":"Neurobiol Dis"},{"issue":"10","key":"55_CR80","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd2681","volume":"7","author":"AG Kazantsev","year":"2008","unstructured":"Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008;7(10):854\u201368.","journal-title":"Nat Rev Drug Discov"},{"issue":"42","key":"55_CR81","doi-asserted-by":"crossref","first-page":"38837","DOI":"10.1074\/jbc.M106779200","volume":"276","author":"CM Grozinger","year":"2001","unstructured":"Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem. 2001;276(42):38837\u201343.","journal-title":"J Biol Chem"},{"issue":"24","key":"55_CR82","doi-asserted-by":"crossref","first-page":"7789","DOI":"10.1021\/jm050100l","volume":"48","author":"A Mai","year":"2005","unstructured":"Mai A, Massa S, Lavu S, Pezzi R, Simeoni S, Ragno R, et al. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone\/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005;48(24):7789\u201395.","journal-title":"J Med Chem"},{"issue":"25","key":"55_CR83","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1021\/jm050522v","volume":"48","author":"AD Napper","year":"2005","unstructured":"Napper AD, Hixon J, McDonagh T, Keavey K, Pons JF, Barker J, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem. 2005;48(25):8045\u201354.","journal-title":"J Med Chem"},{"issue":"10","key":"55_CR84","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/cmdc.200700003","volume":"2","author":"J Trapp","year":"2007","unstructured":"Trapp J, Meier R, Hongwiset D, Kassack MU, Sippl W, Jung M. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). ChemMedChem. 2007;2(10):1419\u201331.","journal-title":"ChemMedChem"},{"issue":"6","key":"55_CR85","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.celrep.2012.11.001","volume":"2","author":"V Chopra","year":"2012","unstructured":"Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, Edgerly C, et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington\u2019s disease mouse models. Cell Rep. 2012;2(6):1492\u20137.","journal-title":"Cell Rep"},{"issue":"3","key":"55_CR86","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.pneurobio.2011.09.001","volume":"95","author":"F Zhang","year":"2011","unstructured":"Zhang F, Wang S, Gan L, Vosler PS, Gao Y, Zigmond MJ, et al. Protective effects and mechanisms of sirtuins in the nervous system. Prog Neurobiol. 2011;95(3):373\u201395.","journal-title":"Prog Neurobiol"},{"key":"55_CR87","doi-asserted-by":"crossref","unstructured":"Donmez G, Outeiro TF. SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med. 2013;5(3):344\u201352.","DOI":"10.1002\/emmm.201302451"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0055-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0055-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0055-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T21:16:28Z","timestamp":1644700588000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0055-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,3]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0055-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,3]]}}}